Fight against COVID-19
Diagnostic antibody & antigen
Services
- Custom AAV Production
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Supports
SOCAIL MEDIA
Pre-made Tilavonemab benchmark antibody ( Whole mAb, anti-MAPT therapeutic antibody, Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-572
Pre-Made Tilavonemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tilavonemab (formerly C2N 8E12) is a humanised recombinant anti-human tau monoclonal antibody, being developed by AbbVie and C2N Diagnostics for the treatment of various neurological disorders including Alzheimer's disease.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-572-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-572-10mg | 10mg | 21890 | ||
| GMP-Bios-ab-572-100mg | 100mg | 148000 | ||
| GMP-Bios-ab-572-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Tilavonemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody |
| INN Name | Tilavonemab |
| Target | MAPT |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | AbbVie;C2N Diagnostics |
| Conditions Approved | na |
| Conditions Active | Alzheimer's disease;Progressive supranuclear palsy |
| Conditions Discontinued | na |
| Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
